Published in J Clin Invest on August 01, 1973
M proteins of group A streptococci. Bacteriol Rev (1974) 3.15
Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun (1988) 2.24
Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev (2014) 2.20
Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med (1988) 1.39
Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med (1979) 1.30
Streptococcal rheumatic carditis. Microbiol Rev (1983) 0.94
Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice. Clin Vaccine Immunol (2010) 0.94
Homologous and heterologous protection of mice with group A streptococcal M protein vaccines. Infect Immun (1977) 0.91
Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun (2005) 0.88
Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever. Infect Immun (1982) 0.86
Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci. PLoS One (2014) 0.83
Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections. Am J Med Sci (2010) 0.81
Strategies in the development of vaccines to prevent infections with group A streptococcus. Hum Vaccin Immunother (2013) 0.80
Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads. Vaccine (2010) 0.80
Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus. J Immunol Res (2015) 0.76
Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate. Hum Vaccin Immunother (2016) 0.75
Purification and serological characterization of a type-specific antigen of Streptococcus equisimilis. Infect Immun (1975) 0.75
Accelerating the development of a group A Streptococcus vaccine: an urgent public health need. Clin Exp Vaccine Res (2016) 0.75
Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models. MBio (2016) 0.75
Current knowledge of type-specific M antigens of group A streptococci. J Immunol (1962) 14.71
Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med (1957) 10.14
An immunological relationship between the group. A streptococcus and mammalian muscle. J Exp Med (1966) 4.89
An immunological cross-reaction between group-A streptococcal cells and human heart tissue. Lancet (1962) 4.78
The multiple molecular structure of the M proteins of group A streptococci. Proc Natl Acad Sci U S A (1965) 2.92
Biological properties of streptococcal cell-wall particles. I. Determinants of the chronic nodular lesion of connective tissue. J Bacteriol (1965) 2.77
Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans. J Exp Med (1966) 1.89
Mimetic relationships between group A streptococci and mammalian tissues. Adv Immunol (1967) 1.83
Primary immunization of infants and children with group A streptococcal M protein. J Infect Dis (1969) 1.38
Prospects for a vaccine against group A streptococci: the problem of the immunology of M proteins. Arthritis Rheum (1967) 1.36
Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA (1969) 1.25
Antigenicity of the M proteins of group A hemolytic streptococci. II. Antibody response in rabbits to vaccines prepared with oil emulsions and aluminum hydroxide. J Immunol (1966) 1.23
Epidemiology of streptococcal infections. Harvey Lect (1957) 1.14
Micro complement fixation assay for type-specific group A streptococcal antibody. Infect Immun (1971) 1.10
Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol (1968) 0.93
A review of past attempts and present concepts of producing streptococcal immunity in humans. Q Bull Northwest Univ Med Sch (1960) 0.88
Antigenicity of the M proteins of group A hemolytic streptococci. V. The absence of antigenic determinants common to mammalian heart muscle. J Immunol (1969) 0.82
ANTIBACTERIAL PROPERTIES OF PROTAMINE AND HISTONE. Science (1942) 3.32
M proteins of group A streptococci. Bacteriol Rev (1974) 3.15
Respiratory and systemic cellular and humoral immune responses to influenza virus vaccine administered parenterally or by nose drops. Cell Immunol (1972) 2.94
The multiple molecular structure of the M proteins of group A streptococci. Proc Natl Acad Sci U S A (1965) 2.92
Nature of the collagen synthesized by a transplanted chondrosarcoma. Arch Biochem Biophys (1975) 2.64
New observations on the structure and antigenicity of the M proteins of the group A streptococcus. Immunochemistry (1969) 2.63
Cell-mediated immunity and antibody responses in the respiratory tract after local and systemic immunization. J Exp Med (1971) 2.54
5-fluorocytosine in the treatment of mycotic infections. Ann Intern Med (1972) 2.40
Hurler's syndrome: biosynthesis of acid mucopolysaccharides in tissue culture. Proc Natl Acad Sci U S A (1966) 2.34
Antigenicity of the M proteins of group A hemolytic streptococci. IV. Cross-reactivity between serotypes. J Immunol (1968) 2.18
The biosynthesis of chondroitin-sulfate protein complex. Proc Natl Acad Sci U S A (1965) 2.17
Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. JAMA (1969) 2.08
Antibody response in respiratory secretions of volunteers given live and dead influenza virus. J Immunol (1968) 1.92
Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans. J Exp Med (1966) 1.89
Stimulation of synthesis of free chondroitin sulfate chains by beta-D-xylosides in cultured cells. Proc Natl Acad Sci U S A (1974) 1.77
Glycosaminoglycan synthesis by cultured human skin fibroblasts after transformation with simian virus 40. J Biol Chem (1977) 1.77
Cell-mediated immunity shown by lymphocytes from the respiratory tract. Science (1970) 1.71
Immunity to infections on secretory surfaces. J Infect Dis (1974) 1.66
Structural studies on heparitin sulfate of normal and Hurler tissues. J Biol Chem (1967) 1.60
The mucopolysaccharidoses (a review). Proc Natl Acad Sci U S A (1976) 1.60
The irreversible inhibition of differentiation of limb-bud mesenchyme by bromodeoxyuridine. Proc Natl Acad Sci U S A (1972) 1.59
Cell-free synthesis of hyaluronic acid in Marfan syndrome. J Biol Chem (1979) 1.58
Optimal antibiotic therapy in cholera. Bull World Health Organ (1968) 1.58
The biosynthesis of chondroitin sulfate. Arch Biochem Biophys (1966) 1.58
Studies on biosynthesis of the linkage region of chondroitin sulfate-protein complex. Proc Natl Acad Sci U S A (1966) 1.57
Stimulation of chondromucoprotein synthesis in chondrocytes by extracellular chondromucoprotein. Proc Natl Acad Sci U S A (1972) 1.50
Translation and characterization of messenger RNAs in differentiating chicken cartilage. Proc Natl Acad Sci U S A (1979) 1.49
Influenza virus neutralizing antibody in human respiratory secretions. J Immunol (1968) 1.48
Influenza infection in ferrets: role of serum antibody in protection and recovery. Infect Immun (1976) 1.48
The biosynthesis of hyaluronic acid by Streptococcus. J Biol Chem (1969) 1.48
Immunoglobulin levels and antibody to Candida albicans in human cervicovaginal secretions. Clin Exp Immunol (1972) 1.45
Hurler's syndrome, an -L-iduronidase deficiency. Biochem Biophys Res Commun (1972) 1.45
Immunosuppression during influenza virus infection. Infect Immun (1974) 1.45
The sulfation of chondroitin sulfate in embryonic chick cartilage epiphyses. J Biol Chem (1969) 1.43
Biosynthesis of hyaluronic acid by Streptococcus. J Biol Chem (1979) 1.40
An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull World Health Organ (1969) 1.40
Probable gallbladder infection in convalescent cholera patients. Lancet (1967) 1.39
Primary immunization of infants and children with group A streptococcal M protein. J Infect Dis (1969) 1.38
Stimulation of synthesis of free chondroitin sulfate chains by beta-D-xylosides in cultured cells. J Biol Chem (1975) 1.38
Balkanization of medical specialties. J Gen Intern Med (1991) 1.38
Acid mucopolysaccharides in cultured human fibroblasts. Lancet (1969) 1.36
Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux-Lamy syndrome. Biochem Biophys Res Commun (1974) 1.36
Construction and partial characterization of two recombinant cDNA clones for procollagen from chicken cartilage. Nucleic Acids Res (1982) 1.35
Biosynthesis of the chondroitin sulfate proteoglycan. Purification and properties of xylosyltransferase. J Biol Chem (1972) 1.33
Secretory IgA in human serum. J Immunol (1970) 1.32
Cellular and antibody reactions to streptococcal M protein types 1, 3, 6 and 12. J Immunol (1970) 1.32
Immune response of the human respiratory tract. I. Immunoglobulin levels and influenza virus vaccine antibody response. J Immunol (1973) 1.30
L-iduronidase in cultured human fibroblasts and liver. Biochem Biophys Res Commun (1971) 1.30
Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions. J Immunol (1976) 1.29
Acid mucopolysaccharides in cultured fibroblasts of cystic fibrosis of the pancreas. Biochem Biophys Res Commun (1968) 1.26
Identification of genomic DNA coding for chicken type II procollagen. J Biol Chem (1983) 1.25
Synthesis of acid mucopolysaccharides by glial tumor cells in tissue culture. Proc Natl Acad Sci U S A (1970) 1.24
Antigenicity of the M proteins of group A hemolytic streptococci. II. Antibody response in rabbits to vaccines prepared with oil emulsions and aluminum hydroxide. J Immunol (1966) 1.23
Intravaginal immunization of humans with Candida albicans. J Immunol (1972) 1.22
The role of hyaluronic acid in intercellular adhesion of cultured mouse cells. Exp Cell Res (1978) 1.21
Concepts and mechanisms of cartilage differentiation. Curr Top Dev Biol (1974) 1.21
Assessing research productivity: evaluating journal publication across academic departments. Acad Med (1989) 1.21
Incorporation of labelled lysine into the desmosine cross-bridges in elastin. Nature (1966) 1.21
Control of chondrogenesis in limb-bud cell cultures by bromodeoxyuridine. Proc Natl Acad Sci U S A (1973) 1.21
Hunter's syndrome: a deficiency of L-idurono-sulfate sulfatase. Biochem Biophys Res Commun (1973) 1.21
Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract. J Infect Dis (1975) 1.20
Morquio's syndrome: deficiency of a chondroitin sulfate N-acetylhexosamine sulfate sulfatase. Biochem Biophys Res Commun (1974) 1.19
Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guérin. J Infect Dis (1977) 1.17
Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis (1978) 1.16
The growth of cartilage cells in soft agar and liquid suspension. J Cell Biol (1970) 1.16
Specificity of respiratory secretion antibody against influenza virus. J Immunol (1970) 1.15
Cholera immunology. II. Serum and intestinal secretion antibody response after naturally occurring cholera. J Infect Dis (1972) 1.13
Aerosol immunization of humans with inactivated parainfluenza type 2 vaccine. N Engl J Med (1970) 1.13
Immune response of the human respiratory tract. II. Cell-mediated immunity in the lower respiratory tract to tuberculin and mumps and influenza viruses. J Infect Dis (1973) 1.10
Micro complement fixation assay for type-specific group A streptococcal antibody. Infect Immun (1971) 1.10
IgE levels in external secretions. Int Arch Allergy Appl Immunol (1973) 1.09
Gastroenteritis: etiology, pathophysiology and clinical manifestations. Medicine (Baltimore) (1979) 1.09
Glycosphingolipids in cultured human skin fibroblasts. I. Characterization and metabolism in normal fibroblasts. J Biol Chem (1972) 1.08
Influenza immunization: field trial on a university campus. J Infect Dis (1972) 1.07
EFFECT OF NICOTINAMIDE ON RESPIRATION OF DYSENTERY BACILLI. Science (1939) 1.07
Effect of isoprinosine against challenge with A(H3N2)-Hong Kong influenza virus in volunteers. Antimicrob Agents Chemother (1973) 1.07
Synthesis and degradation of hyaluronic acid in the cultured fibroblasts of Marfan's disease. J Clin Invest (1973) 1.06
Immune response to phosphorylcholine. IX. Characterization of hybridoma anti-TEPC15 antibodies. J Immunol (1982) 1.04
The enzymic defect in Morquio's disease: the specificity of N-acetylhexosamine sulfatases. Biochem Biophys Res Commun (1978) 1.03
Simultaneous localization of type II collagen and core protein of chondroitin sulfate proteoglycan in individual chondrocytes. Proc Natl Acad Sci U S A (1979) 1.03
Glycolipid and mucopolysaccharide abnormality in fibroblasts of fabry's disease. Science (1969) 1.03
Immunologic mechanisms in hypersensitivity pneumonitis. I. Evidence for cell-mediated immunity and complement fixation in pigeon breeders' disease. J Allergy Clin Immunol (1973) 1.03
Rubella immunization of volunteers via the respiratory tract. Infect Immun (1973) 1.02
Alpha-1-antitrypsin content in the serum, alveolar macrophages, and alveolar lavage fluid of smoking and nonsmoking normal subjects. J Clin Invest (1975) 1.02
An attenuated influenza virus vaccine: Reactogenicity, transmissibility, immunogenicity, and protective efficacy. J Infect Dis (1974) 1.02